PT - JOURNAL ARTICLE AU - Oren Milman AU - Idan Yelin AU - Noga Aharony AU - Rachel Katz AU - Esma Herzel AU - Amir Ben-Tov AU - Jacob Kuint AU - Sivan Gazit AU - Gabriel Chodick AU - Tal Patalon AU - Roy Kishony TI - SARS-CoV-2 infection risk among unvaccinated is negatively associated with community-level vaccination rates AID - 10.1101/2021.03.26.21254394 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.26.21254394 4099 - http://medrxiv.org/content/early/2021/03/31/2021.03.26.21254394.short 4100 - http://medrxiv.org/content/early/2021/03/31/2021.03.26.21254394.full AB - Mass vaccination has the potential to curb the current COVID-19 pandemic by protecting vaccinees from the disease and possibly lowering the chance of transmission to unvaccinated individuals. The high effectiveness of the widely-administered BNT162b vaccine in preventing not only the disease but also infection suggests a potential for a population-level effect, critical for disease eradication. However, this putative effect is difficult to observe, especially in light of highly fluctuating spatio-temporal epidemic dynamics. Here, analyzing vaccination records and test results collected during a rapid vaccine rollout for a large population from 223 geographically defined communities, we find that the rates of vaccination in each community are highly correlated with a later decline in infections among a cohort of under 16 years old which are unvaccinated. These results provide observational evidence that vaccination not only protects individual vaccinees but also provides cross-protection to unvaccinated individuals in the community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the ISRAEL SCIENCE FOUNDATION (grant No. 3633/19) within the KillCorona-Curbing Coronavirus Research Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of Maccabi Healthcare Services, Tel-Aviv, Israel. The IRB includes an exempt from informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to patient privacy concerns, data is only available through a remote server, pending MTA.